ENTA Earnings & Financial Statements
Enanta Pharmaceuticals, Inc.
$12.50
+$0.40(+3.31%)
39
Overall
60
Value
27
Tech
31
Quality
Market Cap
$364.07M
Volume
182.07K
52W Range
$10.20 - $17.15
Target Price
$19.83
ENTA earnings and financial statements: Enanta Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ENTA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $65.32M | $67.64M | $79.20M | $86.16M | $97.07M |
| Operating income | -$85.35M | -$121.69M | -$137.21M | -$123.84M | -$109.57M |
| EBITDA | -$71.28M | -$104.51M | -$123.48M | -$119.22M | -$104.25M |
| Net income | -$81.89M | -$116.05M | -$133.82M | -$121.75M | -$79.00M |
| EPS (diluted) | $-3.84 | $-5.48 | $-6.38 | $-5.91 | $-3.92 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $280.73M | $376.65M | $462.27M | $375.41M | $438.79M |
| Total liabilities | $216.01M | $247.84M | $245.54M | $54.08M | $39.36M |
| Shareholders’ equity | $64.72M | $128.81M | $216.74M | $321.33M | $399.43M |
| Cash and equivalents | $32.30M | $37.23M | $85.39M | $43.99M | $57.21M |
| Long-term debt | $54.76M | $53.94M | $21.24M | $22.37M | $1.13M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$19.27M | -$78.76M | -$103.15M | -$84.78M | -$70.00M |
| Capital expenditure | -$12.90M | -$17.95M | -$9.06M | -$2.13M | -$750.0K |
| Free cash flow | -$32.17M | -$96.71M | -$112.21M | -$86.91M | -$70.75M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ENTA | $12.50 | +3.3% | 182.07K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Enanta Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW